Articles tagged with Cancer Medication
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Researchers from the Universities of Sheffield and Cologne have identified Aurora kinase as a critical protein in Small Cell Lung Cancer (SCLC) survival. Targeted therapeutic strategies focusing on Aurora kinase inhibitors show promise, particularly for patients with MYC gene amplification.
Several new first-in-human studies for drugs targeting a range of cancers have shown promising results, including the development of MEK-, MET- and HSP90 inhibitors as well as immunotherapeutic strategies. Studies have demonstrated significant activity in ALK-positive lung cancer resistant to crizotinib and other targeted therapies.
A landmark survey reveals that many countries fail to provide essential opioid medications for cancer pain relief, leaving hundreds of millions of patients suffering. The study's findings highlight the need to reformulate national plans and repeal excessive restrictions on cancer care.
A phase I/II study found that combining dabrafenib and trametinib delayed the development of treatment resistance in melanoma patients. The combination was at least twice as effective as BRAF inhibition alone, with significant delays in resistance emergence.
Phase I and II trials of combining drugs to treat melanoma, including dabrafenib and trametinib, demonstrate a clinically meaningful improvement in progression-free survival, response rate, and duration of response. These studies suggest the potential for new drug combinations to delay resistance to BRAF inhibitors.
Researchers have found that elevated expression of c-Myc amplifies the activity of all expressed genes in tumor cells, leading to increased transcription and proliferation. This discovery provides a simple explanation for how a single protein can have a profound effect in many types of cancer.
UNM Cancer Center researchers have identified R-ketorolac as a potential treatment for ovarian cancer cells, using flow cytometry and computer modeling to target specific GTPases. Initial animal studies show promising results in controlling tumor growth.
The UCSD-based Chronic Lymphocytic Leukemia Research Consortium will continue its critical work on understanding CLL's development and progression. The five-year grant will enable researchers to develop new drugs and treatments for the disease, which affects over 15,000 people annually in the US.
Researchers at Duke University Medical Center developed a policy to manage drug shortages in hospitals, prioritizing patients based on clinical need and effectiveness. The policy establishes clear rules for apportioning scarce drugs, ensuring fairness and minimizing waste.
Researchers at Northwestern University have identified two promising therapies to treat AMKL: alisertib and dimethylfasudil. Alisertib targets Aurora A kinase and shows promise in mouse models, while dimethylfasudil boosts mature bone marrow cells and inhibits malignant ones.
Researchers Stuart Aaronson and Ross Cagan received a $351,713 grant from the National Cancer Institute to investigate signaling pathways responsible for Wnt oncogene addiction. They aim to discover potent drugs that can disrupt this addiction in tumor cells, increasing the efficacy of therapy for Wnt-activated human cancers.
A new study found that split-dose preparation significantly improved polyp detection rates and adenoma detection rates, as well as the quality of bowel prep and colonoscopy completion rates. This approach involves dividing the preparation into two doses, taken before and after the procedure, to improve patient compliance and efficacy.
Researchers will examine cancer cell drug resistance and focus on prevention strategies using breast cancer as a proof-of-concept model. The goal is to minimize the probability of drug-resistant cancer cells emerging, which are a major cause of current cancer treatment failure.
Researchers at Weill Cornell Medical College reveal that taxanes work by stopping protein movement in cancer cells, not just cell division. This understanding could lead to novel therapies and improved treatment outcomes for prostate cancer patients.
A phase 3 trial confirms abiraterone acetate's efficacy in extending average survival time to 15.8 months for castration-resistant prostate cancer patients. The treatment, which blocks testosterone production, also has a good safety profile.
A large Taiwanese study of 35,871 patients with newly diagnosed shingles found no increased risk of cancer. The study suggests that enhanced surveillance for cancer after a shingles diagnosis is unnecessary, according to the authors.
Researchers at MD Anderson Cancer Center have identified a promising therapy for NRAS-mutant melanoma patients. By combining two drugs that inhibit proteins Mek and Cdk4, scientists found that the combination shrinks tumors in genetically engineered mouse models.
A whole-genome scan can help identify large-scale chromosomal damage, enabling doctors to choose the most effective treatment option for children with neuroblastoma. The study recommends that all children diagnosed with neuroblastoma worldwide have a whole-genome scan as part of their treatment.
Researchers at URMC found that defective cholesterol exportation appears to be a key component in various cancers. They demonstrated that re-establishing the cholesterol export function in human colon cancer cells inhibited tumor growth.
Scientists at Karolinska Institutet developed a new technique using under-twisted DNA origami to deliver cancer drugs, such as doxorubicin, directly to tumor cells while minimizing harm to surrounding healthy tissue. This approach allows for slower release of the drug, enabling more effective treatment at lower concentrations.
Researchers at UNC Health Care have discovered a prime suspect for new cancer drug development: the CIB1 protein. Decreasing CIB1 in cancer cells causes cell death, but the exact mechanism was unknown until now.
A new study found that smokers with lung cancer have 10 times more genetic mutations than those who have never smoked. The researchers identified over 3,700 mutations across all patients and found at least one mutated gene in each non-smoking patient that can be targeted with existing drugs.
Researchers have created a new type of miniature pump activated by body heat that could be used in drug-delivery patches powered by fermentation. The micropump utilizes temperature-dependent gas generation through yeast fermentation to push against a membrane, pumping for several hours.
A new study shows that combining a protein inhibitor with VEGF targeting could more effectively treat diseases by shutting down abnormal blood vessel growth. This approach may also lead to improved treatments for eye diseases and autoimmune disorders.
A new study found a potential link between recreational marijuana use and an increased risk of developing subtypes of testicular cancer. The research suggests that marijuana may trigger carcinogenesis in the testis through the endocannabinoid system.
The public favors treating patients with serious conditions, including cancer, if it reduces burden on carers or offers substantial health benefits. However, the majority oppose a ring-fenced budget for cancer drugs, which would prioritize cancer treatments over other equally serious conditions.
A genome-wide scan of small cell lung cancers reveals an association between SOX2 gene amplification and aggressive disease. Overproduction of SOX2 proteins may ignite or sustain abnormal cell growth in the lung.
Researchers at Karolinska Institutet in Sweden have discovered that sorafenib can effectively treat multiple myeloma by inducing cell death in human myeloma cell lines. The study found that the drug also prevented or delayed disease progression in live mice, supporting its use as a treatment for this blood cancer.
Stephen Byers, a Georgetown Lombardi Comprehensive Cancer Center professor, has been awarded a $2.5 million NCI grant to investigate how certain drugs may prevent cancer. The research aims to understand the mechanism of action of anti-inflammatory drugs that have shown promise in preventing cancer and rheumatoid arthritis.
Researchers analyzed data from 29,423 adult patients and found no statistically significant increased risk of any type of cancer in those treated with biologic response modifiers. This study provides reassuring information for patients considering these therapies for their disease.
Researchers explored the effectiveness of resveratrol in preventing head and neck cancer in Fanconi anemia patients, a rare genetic disorder affecting DNA repair. The study found that resveratrol may eliminate cancer cells in these patients by making them sensitive to certain drugs.
Researchers suggest a 'cyber war' on cancer by breaking the code of cancer cells' social behavior, similar to bacterial colonies. This approach could help prevent dormancy and reawaken cells for targeted chemotherapy attacks.
Researchers at University of Missouri have developed a new cancer drug with exceptional potency, outperforming current treatments by 10 times. The carborane-based drug efficiently targets energy production in cancer cells, minimizing side effects and increasing therapy effectiveness.
Researchers used an experimental cancer drug to treat abnormal brain cell growth in mice with neurofibromatosis 1. The study showed that early treatment can prevent learning disabilities in these children by promoting normal neural stem cell development.
A study published in the Journal of Thoracic Oncology found that patients with low thymidylate synthase (TS) levels and high fibroblast growth factor stimulator (FPGS) levels respond better to pemetrexed treatment. This combination predicts longer survival durations.
A Phase I/II trial tests the safety and efficacy of PR610 in patients with advanced cancer. The study aims to deliver a targeted approach, activating the compound in tissues with low oxygen levels characteristic of many cancers.
A multicenter study found that taking aspirin is associated with a lower risk of death from prostate cancer, especially in high-risk disease. The study analyzed data from almost 6,000 men with prostate cancer treated with surgery or radiotherapy, and the results showed a significant reduction in mortality rates and cancer recurrence.
A recent University of Colorado Cancer Center case study found a patient with ALK+ lung cancer who tested negative for the EML4-ALK fusion gene using the FDA-approved FISH assay, yet showed dramatic response to crizotinib. Next-gen sequencing revealed genetic shards that may have avoided detection by the test.
A drug trial found that TAS-102 improved survival time, reduced risk of death, and controlled disease progression in patients with advanced, inoperable colorectal cancer. Patients treated with TAS-102 had a median overall survival of 9 months, compared to 6.6 months for the placebo group.
Researchers are developing drugs that exploit the body's natural immune system to fight diseases. These 'antibody-recruiting molecules' can be taken orally and induce a patient's own antibodies to fight disease.
A study published in Cancer Research identified a gene that disrupts the inflammatory process implicated in liver cancer. Laboratory mice bred without this gene lacked pro-inflammatory protein TREM-1 and protected themselves from developing liver cancer after exposure to carcinogens.
Researchers at Moffitt Cancer Center report on immune-related adverse events associated with ipilimumab and tremelimumab, two anti-CTLA-4 antibodies used in treating metastatic melanoma. The study highlights the importance of early recognition and management of these side effects to improve treatment outcomes.
A University of Rochester Medical Center study challenges traditional treatment guidelines for early-stage follicular lymphoma, concluding that six different therapies can bring remission. Careful patient staging is key to predicting prognosis and superior progression-free survival.
Scientists have discovered that thiabendazole, a generic antifungal drug, can decrease blood vessel growth in tumors, starving them of nutrients. The study also found that the drug slows tumor growth, suggesting it could be used in combination with other chemotherapies.
Scientists have developed a new material to restore lost flexibility in human vocal cords, which can help alleviate voice loss due to aging, disease, or medical procedures. The material, called polyethylene glycol 30 (PEG30), is flexible and can vibrate like human vocal cords.
A new technology developed by scientists can authenticate drugs in minutes, helping patients in developing countries receive real treatments instead of counterfeit ones. The device uses mass spectrometry and can distinguish between genuine and fake medications.
A new study published in the journal Stroke found that black stroke survivors had higher blood pressure a year after their initial stroke. High blood pressure is a significant risk factor for having another stroke, and controlling it can cut the risk in half.
Computer simulations shed light on the dynamic structure of the LSD1/CoREST protein complex, a major target for therapies. The study reveals that binding to histone H3 triggers significant changes in shape, which may help develop epigenetic drugs that reprogram cancer cells.
A phase III clinical trial shows Enzalutamide extends life by five months, with significant survival benefits and reduced side effects compared to traditional chemotherapy. The study also reveals improved measures including PSA blood levels and progression-free survival.
A new study finds that enzalutamide significantly extends life and improves quality of life in men with advanced prostate cancer. The fourth drug in two years to demonstrate this effect, it offers improved treatment options for men with the disease.
Researchers uncover chromosomal translocations that cause cancer, potentially leading to targeted therapies and personalized treatment. The study's findings may enable doctors to offer more accurate prognoses and inform treatment decisions.
Researchers have identified an experimental drug, GSIs, that blocks Notch and prevents lung cancer growth in mice without treatment-related side effects. This discovery brings new clues for the treatment of lung cancer and is being tested in co-clinical trials.
A new method allows for personalized clinical trial predictions by analyzing cell behavior, offering ways to improve cancer treatment outcomes and predict tumor response. The approach may enable oncologists to test combinations of targeted therapies in individual patient tumors.
A blood test detecting high levels of lactate dehydrogenase (LDH) may guide treatment for advanced kidney cancer, extending survival and improving outcomes for patients. Researchers found that LDH levels can predict the effectiveness of mTOR inhibitor temsirolimus in treating late-stage kidney cancer.
Researchers from the University of Cambridge have developed injectable hydrogels that can deliver therapeutics for up to six months, doubling current maximum release time. These hydrogels contain proteins or other therapeutics and are capable of controlled release rate according to material ratio.
Researchers at Case Western Reserve University have identified a new oncogene, FAM83B, which contributes to the development of breast cancer. Elevated expression of this gene is associated with the more aggressive triple-negative subgroup, highlighting the need for new therapeutic options.
A new study has found that patients taking thiazolidinedione (TZD) diabetes drugs are two to three times more likely to develop bladder cancer than those who took sulfonylurea drugs. The risk is especially high among Type 2 diabetes patients, with 170 expected cases per 100,000 treated with TZDs.
A recent pooled analysis of randomized trials found a significant decrease in overall cancer mortality associated with daily aspirin use. The study, which looked at data from over 100,000 participants, found a 37% reduction in overall cancer death risk during a five-year follow-up analysis.
Researchers developed a new prostate cancer screening method that combines drug therapy with changes in PSA levels to identify men with high-risk prostate cancer. The study showed that using PSA with these drugs can help differentiate between prostate cancer and benign disease, even in patients with difficult diagnoses.
Researchers have identified sphingosine kinase as a key player in promoting resistance to breast cancer therapies, such as tamoxifen. Targeted inhibition of SK has shown potential in inducing cell death and blocking tumor growth in drug-resistant models.